Updates in the treatment of neovascular glaucoma: From conventional approaches to novel therapies

新生血管性青光眼治疗进展:从传统方法到新型疗法

阅读:1

Abstract

Neovascular glaucoma (NVG) is a severe and refractory form of secondary glaucoma characterized by the proliferation of abnormal vessels in the anterior segment, leading to a progressive rise in intraocular pressure (IOP) and optic nerve damage. It is most commonly associated with ischemic retinal conditions such as diabetic retinopathy, central retinal vein occlusion, and ocular ischemic syndrome. This review aims to provide an updated overview of the current management strategies for NVG, including recent advancements in medical, laser, and surgical treatment modalities. While anti-vascular endothelial growth factor (VEGF) agents have revolutionized early NVG management, panretinal photocoagulation (PRP) remains the cornerstone of ischemia management, with enhancements in laser delivery improving efficacy and safety. Filtration surgeries like trabeculectomy and glaucoma drainage devices offer equivocal results in NVG, and on the other hand, safer cyclodestructive methods like transscleral micropulse and endoscopic cyclophotocoagulation (ECP) have emerged as promising alternatives with reduced complications. The management of NVG requires a multimodal approach involving the primary physician, retina specialist, and a glaucoma specialist with treatment tailored to disease severity and underlying retinal pathology. Further research is needed to optimize treatment algorithms and explore emerging therapies for this challenging condition.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。